Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study

Table 4 Comparison of platelet crit at baseline and post-treatment in the different platelet count groups

	Baseline (%)	Post-treatment (%)	Change (%)	P value1
Group I (n = 25)				0.0182
mean ± SD	0.02 ± 0.01	0.08 ± 0.06	0.06 ± 0.05
Median	0.02	0.08	0.05
IQR	0.01-0.03	0.02-0.12	0.01-0.10
Min, max	0.01, 0.03	0.01, 0.18	0.00, 0.15
Group II (n = 43)				< 0.0013
mean ± SD	0.05 ± 0.04	0.13 ± 0.09	0.08 ± 0.11
Median	0.05	0.09	0.05
IQR	0.04-0.05	0.07-0.16	0.03-0.11
Min, max	0.03, 0.26	0.01, 0.51	-0.19, 0.46
Group III (n = 32)				< 0.0014
mean ± SD	0.07 ± 0.01	0.17 ± 0.09	0.10± 0.10
Median	0.07	0.17	0.07
IQR	0.06-0.08	0.09-0.25	0.01-0.18
Min, max	0.05, 0.09	0.04, 0.36	-0.04, 0.29

¹Wilcoxon rank sum test.

²Data were analyzed by 8 patients.

³PThis was an analysis of 31 patients.

⁴Date were analyzed by 19 patients.